Bicycle Therapeutics (BCYC) Share-based Compensation (2018 - 2026)

Bicycle Therapeutics has reported Share-based Compensation for 9 years, with the latest figure at $6.9 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 27.85% year-over-year to $6.9 million; the trailing twelve-month figure through Mar 2026 stood at $36.8 million (down 4.21% YoY), and the FY2025 full-year result was $39.5 million, up 3.63% from the prior year.
• Share-based Compensation for Q1 2026 stood at $6.9 million, down from $11.7 million in the prior quarter.
• The five-year high for Share-based Compensation was $11.7 million in Q4 2025, with the low at $5.4 million in Q3 2022.
• Historically, Share-based Compensation has averaged $8.5 million across 5 years, with a median of $9.0 million in 2023.
• Annual changes were most pronounced in 2022 — Share-based Compensation jumped 166.89% — and 2026, when it retreated 27.85%.
• Bicycle Therapeutics' Share-based Compensation stood at $5.5 million in 2022, then jumped by 41.01% to $7.8 million in 2023, then jumped by 32.27% to $10.3 million in 2024, then climbed by 12.77% to $11.7 million in 2025, then plunged by 40.53% to $6.9 million in 2026.
• The last three Share-based Compensation figures came in at $6.9 million (Q1 2026), $11.7 million (Q4 2025), and $8.8 million (Q3 2025), per Business Quant data.